C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors Cuts Stock Position in Johnson & Johnson (NYSE:JNJ)

C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors lowered its holdings in Johnson & Johnson (NYSE:JNJ) by 28.4% in the fourth quarter, HoldingsChannel reports. The firm owned 7,309 shares of the company’s stock after selling 2,901 shares during the quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors’ holdings in Johnson & Johnson were worth $1,057,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the business. AMF Tjanstepension AB grew its position in shares of Johnson & Johnson by 14.2% during the third quarter. AMF Tjanstepension AB now owns 425,261 shares of the company’s stock worth $68,985,000 after buying an additional 52,997 shares in the last quarter. Alpha Financial Partners LLC acquired a new position in Johnson & Johnson during the 3rd quarter worth approximately $209,000. Wealth Group Ltd. purchased a new stake in shares of Johnson & Johnson in the 3rd quarter valued at approximately $213,000. Creative Planning raised its holdings in shares of Johnson & Johnson by 4.3% in the 3rd quarter. Creative Planning now owns 988,403 shares of the company’s stock valued at $160,181,000 after purchasing an additional 41,082 shares in the last quarter. Finally, Swedbank AB lifted its position in shares of Johnson & Johnson by 5.3% during the 3rd quarter. Swedbank AB now owns 2,215,108 shares of the company’s stock worth $358,980,000 after purchasing an additional 111,570 shares during the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Trading Down 0.7 %

NYSE:JNJ opened at $156.20 on Friday. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. The stock’s 50 day simple moving average is $147.87 and its 200-day simple moving average is $156.00. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $168.85. The firm has a market cap of $376.08 billion, a P/E ratio of 23.49, a PEG ratio of 2.46 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The company had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. During the same quarter in the prior year, the firm earned $2.29 EPS. Johnson & Johnson’s quarterly revenue was up 5.3% on a year-over-year basis. Equities analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.18%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is 74.59%.

Wall Street Analysts Forecast Growth

JNJ has been the topic of a number of analyst reports. Stifel Nicolaus cut their price target on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating on the stock in a research note on Thursday, January 23rd. Raymond James decreased their target price on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a research note on Thursday, January 23rd. Wolfe Research assumed coverage on shares of Johnson & Johnson in a research note on Friday, November 15th. They issued an “outperform” rating and a $190.00 price target on the stock. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 25th. Finally, Argus upgraded shares of Johnson & Johnson to a “strong-buy” rating in a research note on Friday, January 24th. Nine investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $170.67.

Insider Activity

In other Johnson & Johnson news, Director Mark A. Weinberger acquired 1,000 shares of the business’s stock in a transaction on Thursday, December 12th. The stock was purchased at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the transaction, the director now owns 1,000 shares of the company’s stock, valued at $147,220. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.